GSK sees shingles vaccine sales rising, as free cash flow concerns weigh
GSK sees shingles vaccine sales rising, as free cash flow concerns weigh Reuters GlaxoSmithKline forecast on Wednesday that 2019 sales of its shingles vaccine would be more than 1 billion pounds ($1.